Future studies should assess whether manipulating MCCC1 expression—via knockdown, pharmacological inhibition, or other strategies—can mitigate PD-like phenotypes, particularly in the context of α-synuclein aggregation and mitochondrial dysfunction. This evidence concerns the gene MCCC1 and Parkinson disease.